Dr. David Townshend completed the first procedures at North Tyneside General Hospital in the UK. They mark the start of the company’s UK Infinity with Adaptis and Everlast study.
“We are delighted to have implanted the first patient using Stryker’s Infinity Total Ankle System with Adaptis and Everlast technology as part of the UK post-market clinical study,” said Townshend. “This new technology marks the next step of the Infinity Total Ankle System which has already shown promising outcomes and survivorship for our patients with end-stage ankle arthritis. We look forward to sharing the results of this clinical study.”
Infinity Total Ankle features a titanium alloy tibial tray, cobalt chromium talar dome and polyethylene insert. It has a low-profile tibial implant design as well.
Stryker designed the Adaptis 3D-printed total ankle implants to incorporate porous metal components. These act as a scaffold, facilitating boney ingrowth. Everlast, highly cross-linked polyethylene inserts blended with Vitamin E, can improve wear resistance.
The two talar options bring interchangeability, adding versatility to the Infinity system so it can cater to diverse patient needs. Stryker also optimized the system for efficiency through its Prophecy Surgical Planning platform, which includes patient-specific instruments.
“Infinity with Adaptis builds on the legacy of the original Infinity Total Ankle, with a decade of clinical use. Recent publication data showed a 98.8% survivorship at two years of the original Infinity implant, demonstrating its safety and efficacy as a low-profile prosthesis for surgeons treating end-stage ankle arthritis,” said Markus Ochs, VP and GM of Stryker’s European Trauma & Extremities business. “These initial procedures highlight Stryker’s dedication to innovation and commitment through research, enhancing our collaboration with surgeons.”
